Water-soluble vitamin
Vitamin C
Vitamin C has an app half-life of about 8 hours, while a 2024 trial introduction gives 10 to 20 days as the average half-life of the vitamin C stored in the body, not a plasma elimination time, and says plasma peaks within 120 to 180 minutes of ingestion.1
Vitamin C after one dose: 50% at ~8 h, 25% at 16 h, 12.5% at 24 h.
Drawn from the half-life in the app's model, ~8 h. The model's figures
- Compound
- Vitamin C
- Symbol
- C
- Family
- Supplements
- Parts
- 13
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Vitamin C (L-ascorbic acid) is a water-soluble vitamin that, in the words of a 2024 trial's introduction, humans "must acquire" through diet because they lack the enzyme gulonolactone oxidase.1 The app files vitamin C as a supplement in the vitamin sub-category, with an oral route and a typical range of 500 to 2000 mg per day. The app grades the evidence as strong; that grade is the app's own and the studies below are described with their own limits. The app's note says absorption falls above about 200 mg per dose; a 1996 finding in 7 hospitalised volunteers was that bioavailability "was complete for 200 mg of vitamin C as a single dose" and declined at single doses of 500 mg and higher, with no single-dose figure between 200 and 500 mg in the summary.2 The app's note also says liposomal vitamin C gives about 2 to 5 times the absorption; the two liposomal sources report smaller or wider ranges, described below.
How it works
The introduction to a 2024 randomised trial describes vitamin C as a co-factor that "facilitates collagen biosynthesis, carnitine, and catecholamine metabolism, and enables dietary iron absorption".1 In the 1996 depletion-repletion study, neutrophils, monocytes and lymphocytes saturated at 100 mg daily and "contained concentrations at least 14-fold higher than plasma".2 Padayatty and colleagues concluded that "Oral vitamin C produces plasma concentrations that are tightly controlled".4 In healthy young women, Levine and colleagues measured F2-isoprostanes, markers of endogenous oxidant stress, and reported them "unchanged by vitamin C at all doses", which they read as "suggesting this vitamin does not alter endogenous lipid peroxidation in healthy young women"; plasma samples were available from only seven subjects.3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~8 h
- Bioavailability
- 50%
- Typical dose
- 500–2000 mg/day
- Route
- Oral
- Time to peak
- ~3 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~8 h | An average half-life of 10–20 days for the vitamin C stored in the body, not a plasma elimination time, stated in the introduction of a 2024 trial, which also says the average adult stores 1.2–2.0 g of vitamin C in the body1 |
| Bioavailability | 50% | Complete for a single 200 mg dose in 7 hospitalised volunteers, declining at single doses of 500 mg and higher; the summary gives no single percentage across doses2 |
| Time to peak | ~3 h | Plasma concentrations peak within 120 to 180 minutes of ingestion (2024 trial introduction); in that trial's own 500 mg crossover, all participants had a plasma Tmax of 4 h on standard vitamin C, with samples drawn at 3, 4 and 6 hours1 |
| Plasma saturation | Not an app field | Complete plasma saturation at 1000 mg daily in 7 hospitalised volunteers; plasma and circulating cells saturated at 400 mg daily in hospitalised young women2,3 |
| Oral against intravenous | Route: oral | At 1.25 g, mean peak plasma concentration 134.8 ± 20.6 micromol/L orally and 885 ± 201.2 micromol/L intravenously in 17 hospitalised volunteers4 |
| Volume of distribution, absorption rate | Not set in the app | No figure in the sources read |
The app's 8-hour half-life differs from the only half-life figure in the sources read, the 10 to 20 days in the 2024 trial's introduction, which is a statement about the average half-life of the body pool and not a measured plasma elimination time.1 Carr's 2025 scoping review notes that most of the liposomal studies "did not report baseline ascorbate concentrations" and that plasma peaks after oral doses are seen only "if participants already have adequate ascorbate status".5
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Levine and colleagues, PNAS 19962 | In-hospital depletion-repletion study2 | 7 healthy volunteers2 | Seven daily doses of vitamin C from 30 to 2500 mg, orally, over 4 to 6 months in hospital2 | Sigmoid dose-concentration curve; complete plasma saturation at 1000 mg daily; oxalate and urate excretion elevated at 1000 mg daily compared with lower doses2 |
| Levine and colleagues, PNAS 20013 | In-hospital depletion-repletion study3 | 15 healthy young women aged 19 to 27, with data not available for all subjects at all doses3 | Vitamin C 30 to 2,500 mg daily, for 186 ± 28 days of hospitalisation3 | Sigmoidal dose-concentration relationship; plasma and circulating cells saturated at 400 mg daily; F2-isoprostanes unchanged at all doses, with plasma samples from only seven subjects3 |
| Padayatty and colleagues, Annals of Internal Medicine 20044 | Dose-concentration studies and pharmacokinetic modelling4 | 17 healthy hospitalised volunteers4 | Oral and intravenous doses from 0.015 to 1.25 g; higher doses modelled, not given4 | At 1.25 g, mean peak plasma 134.8 ± 20.6 micromol/L orally against 885 ± 201.2 micromol/L intravenously4 |
| Hemilä and Chalker, Cochrane Database of Systematic Reviews 20136 | Systematic review and meta-analysis of placebo-controlled trials6 | 29 trial comparisons with 11,306 participants for incidence; general community trials 10,708 participants6 | Regular or therapeutic vitamin C at 0.2 g per day or more, as trial doses varied6 | Community incidence RR 0.97 (95% CI 0.94 to 1.00); 598 marathon runners, skiers and soldiers RR 0.48 (0.35 to 0.64); duration reduced 8% in adults and 14% in children; no consistent effect in therapeutic trials6 |
| Sesso and colleagues, Physicians' Health Study II, JAMA 20087 | Randomised, double-blind, placebo-controlled factorial trial with vitamin E7 | 14,641 US male physicians aged 50 years or older at entry, 754 with prevalent cardiovascular disease7 | Vitamin C 500 mg daily (with vitamin E 400 IU every other day in the factorial design); mean follow-up 8 years7 | Major cardiovascular events 10.8 against 10.9 per 1000 person-years, HR 0.99 (95% CI 0.89-1.11; P = .91); total mortality HR 1.07 (0.97-1.18)7 |
| Ferraro and colleagues, American Journal of Kidney Disease 20168 | Prospective cohort analysis8 | 156,735 women (Nurses' Health Study I and II) and 40,536 men (Health Professionals Follow-up Study)8 | Self-reported intake from food-frequency questionnaires; median follow-up 11.3 to 11.7 years8 | Supplemental intake of 1,000 mg/d or more against no supplemental use: HR 1.19 (95% CI 1.01-1.40) in men; HR 0.90 (95% CI 0.79-1.04) in women8 |
| Purpura and colleagues, European Journal of Nutrition 20241 | Randomised, double-blind, placebo-controlled crossover; funded by Specnova, LLC1 | 27 healthy adults (19 males, 8 females)1 | Single oral doses of placebo, 500 mg vitamin C and 500 mg liposomal vitamin C, 3 days apart, blood sampled over 24 h1 | Liposomal against standard: plasma Cmax +27%, AUC0-24 +21%; leukocyte Cmax +20%, AUC0-24 +8%1 |
| Carr, Basic and Clinical Pharmacology and Toxicology 20255 | Scoping review of liposomal against non-liposomal ascorbate5 | 10 studies included from 321 identified; seven randomised crossover, one parallel groups, two non-randomised5 | Ascorbate doses 0.15 to 10 g; sample collection 4 to 24 h5 | Nine studies showed higher liposomal bioavailability: 1.2 to 5.4-fold Cmax and 1.3 to 7.2-fold AUC; none assessed elimination5 |
Deeper analysis: Levine depletion-repletion studies
Levine and colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, reported a depletion-repletion study in Proceedings of the National Academy of Sciences in 1996.2 Seven healthy volunteers were hospitalised for 4 to 6 months on a diet containing less than 5 mg of vitamin C daily, and steady-state plasma and tissue concentrations were measured at seven daily doses from 30 to 2500 mg.2 Urinary results were that "No vitamin C was excreted in urine of six of seven volunteers until the 100-mg dose", while at single doses of 500 mg and higher the absorbed amount was excreted.2 The authors concluded that "Safe doses of vitamin C are less than 1000 mg daily, and vitamin C daily doses above 400 mg have no evident value".2 The record lists no funding statement, and the saved text holds the summary and reference list but not the body, so the authors' own limitations are not quoted here; the sample was 7 volunteers.2
Levine, Wang, Padayatty and Morrow repeated the design in healthy young women in 2001, with the same dose range of 30 to 2,500 mg daily and a hospital stay of 186 ± 28 days.3 They report that "Plasma and circulating cells saturated at 400 mg daily, with urinary elimination of higher doses".3 The 2001 record lists grants from the National Institute of Diabetes and Digestive and Kidney Diseases (including DK48831) and other NIH institutes; in the text the authors note that "The data here are from young women" and that plasma F2-isoprostane samples were available from only seven subjects.3
Deeper analysis: Padayatty oral and intravenous pharmacokinetics
Padayatty and colleagues, Annals of Internal Medicine, 2004, studied 17 healthy hospitalised volunteers with oral and intravenous doses of 0.015 to 1.25 g and then modelled doses of 1 to 100 g.4 Peak plasma concentrations "were higher after administration of intravenous doses than after administration of oral doses", and the difference increased with dose.4 The authors state the limitation that "Patient data are not available to confirm pharmacokinetic modeling at high doses and in patients with cancer".4 The record lists an intramural NIH grant (NIDDK Z01 DK 54506); the saved text is the summary and author list only, so author disclosures and any commercial ties could not be checked.4
Deeper analysis: Cochrane review of the common cold
Hemilä and Chalker, in the Cochrane Database of Systematic Reviews in 2013, searched CENTRAL, MEDLINE (1966 to November week 3, 2012), EMBASE and other databases for placebo-controlled trials using 0.2 g per day or more.6 The review reports 29 trial comparisons with 11,306 participants for the risk of catching a cold, and in the general community trials (10,708 participants) the pooled RR was 0.97 (95% CI 0.94 to 1.00).6 Five trials in 598 marathon runners, skiers and soldiers on subarctic exercises gave a pooled RR of 0.48 (95% CI 0.35 to 0.64), and the review notes that in these trials "The doses of vitamin C were not particularly high, being between 0.25 and 1.0 g/day".6 For duration, 31 comparisons covering 9745 episodes showed colds shortened by 8% (3% to 12%) in adults and 14% (7% to 21%) in children, and by 18% in children given 1 to 2 g per day.6 The null result sits beside these: for the 7 therapeutic comparisons (3249 episodes), "No consistent effect of vitamin C was seen on the duration or severity of colds in the therapeutic trials".6 The review reports "substantial heterogeneity" in the incidence analysis (Chi2 P = 0.02, I2 38%).6 The review lists the Commonwealth Department of Health and Ageing, Australia, as an external source of support and the Australian National University as an internal source, and states that "None of the other review authors have any conflict of interest to declare in this review".6
Deeper analysis: Physicians' Health Study II
Sesso and colleagues at Brigham and Women's Hospital and Harvard reported the Physicians' Health Study II in JAMA in 2008.7 It was a "randomized, double-blind, placebo-controlled factorial trial of vitamin E and vitamin C" that began in 1997 and ran to 31 August 2007, in 14,641 US male physicians initially aged 50 years or older.7 Over a mean follow-up of 8 years there were 1245 confirmed major cardiovascular events, and the vitamin C result was 10.8 against 10.9 events per 1000 person-years (HR 0.99, 95% CI 0.89-1.11; P = .91).7 Secondary outcomes were also null for vitamin C: total myocardial infarction HR 1.04 (0.87-1.24), total stroke HR 0.89 (0.74-1.07), cardiovascular mortality HR 1.02 (0.85-1.21) and total mortality HR 1.07 (0.97-1.18).7 In the 754 men with cardiovascular disease at baseline, total myocardial infarction occurred in 18 on vitamin C and 31 on placebo (HR 0.57; 95% CI 0.32 to 1.02; P = 0.06), which the authors call "interesting, but confined to a small subgroup".7 On safety, the authors "observed no significant differences in adverse effects, including hematuria, easy bruising, and epistaxis, for active vitamin E or C compared with placebo", and "There was also no effect of vitamin C on hemorrhagic stroke"; the increase in hemorrhagic stroke (HR 1.74) was in the vitamin E comparison.7 The authors name limitations: "an even longer period of vitamin supplementation may be necessary to cover the critical etiologic window", and "more comprehensive clinical trial data on individual vitamin C supplemental use at different doses and in other populations remain lacking".7 The record lists National Cancer Institute and National Heart, Lung, and Blood Institute grants, and states that "BASF, Wyeth Pharmaceuticals, and DSM Nutritional Products, Inc had no role in the study design".7 Its disclosures state that Dr. Christen "has received research funding support from the National Institutes of Health, Harvard University (Clinical Nutrition Research Center), and DSM Nutritional Products, Inc (Roche)", and that Dr. Manson received "assistance with study pills and packaging from BASF and Cognis".7 The disclosures also list research funding to Dr. Sesso from Roche Vitamins, Inc (now DSM Nutritional Products, Inc), study agents and packaging to Dr. Buring from Bayer Healthcare and the Natural Source Vitamin E Association, research funding to Dr. Kurth from Bayer AG, and consulting or honoraria to Dr. Gaziano from Bayer AG and Pfizer.7
Deeper analysis: kidney stone cohorts
Ferraro and colleagues analysed prospective cohorts: 156,735 women in the Nurses' Health Study I and II and 40,536 men in the Health Professionals Follow-up Study.8 Over a median follow-up of 11.3 to 11.7 years, 6,245 incident kidney stones were identified.8 In men, hazard ratios for total vitamin C intake rose across the categories to 1.43 (95% CI 1.15-1.79) at 1,000 mg/d or more (P for trend = 0.005), against no significant association in women.8 The null result: "Dietary vitamin C intake was not associated with stones among men or women", although few participants had dietary intakes above 700 mg/d.8 The authors list limitations including that "the possibility of unmeasured or residual confounding factors cannot be excluded", intakes derived from food-frequency questionnaires, no stone composition or 24-hour urine data for most participants, and that the cohorts were "predominantly white".8 The study was supported by National Institutes of Health grants, and its text states that "The funders of this study had no role in study design"; the text also lists consulting disclosures for Dr Curhan (Allena Pharmaceuticals, AstraZeneca, Exponent) and Dr Ferraro (BioHealth Italia).8
Deeper analysis: liposomal vitamin C trial and scoping review
Purpura, Jäger and colleagues reported a randomised, double-blind, placebo-controlled crossover trial in the European Journal of Nutrition in 2024, in which 27 participants (19 males, 8 females) took single doses of placebo, 500 mg vitamin C and 500 mg liposomal vitamin C.1 Plasma Cmax values were reported as "LV-VIT C 8,610 ± 182 ng/mL, VIT C 6,271 ± 444, PLA 379 ± 59", and the authors state that liposomal vitamin C "significantly increased maximum plasma (+ 27%) and leukocytes (+ 20%) concentrations compared to non-liposomal vitamin C".1 The report states that "None of the participants reported any adverse events during or after the study period".1 The trial was funded by Specnova, LLC, whose LipoVantage product was the liposomal arm, and the authors declare no conflict of interest.1 The article text retrieved contains no section or paragraph on limitations; the design was a single 500 mg dose in healthy adults, with 24 hours of sampling.1 Carr's 2025 scoping review of 10 studies reports that "Vastly different liposomal formulations, ascorbate doses (0.15-10 g) and sample collection durations (4-24 h) were used, thereby making it difficult to directly compare the studies".5 Nine of the 10 showed higher bioavailability of the liposomal form, but "none of the studies assessed ascorbate elimination".5 The review's author declares no conflicts of interest and states that "The author received no specific funding for this work".5 The review states that "All of the studies had industry funding and/or authors who were employed by companies".5
Doses reported in studies and on labels
No product label for oral vitamin C was retrieved, so the table lists doses used in the studies read; the app's typical range is 500 to 2000 mg per day.
| Setting | Dose and route | Duration | People and comparator | Reference |
|---|---|---|---|---|
| Depletion-repletion, men | 30 to 2500 mg daily, oral (seven doses) | 4 to 6 months in hospital | 7 healthy volunteers, dose-by-dose comparison | 2 |
| Depletion-repletion, women | 30 to 2,500 mg daily, oral | 186 ± 28 days in hospital | Healthy young women, dose-by-dose comparison | 3 |
| Oral against intravenous | 0.015 to 1.25 g oral and intravenous; 3 g every 4 hours (the maximum tolerated oral dose) was modelled, not given | Not stated in the summary | 17 healthy hospitalised volunteers, oral against intravenous | 4 |
| Common cold, prophylactic trials in stressed groups | 0.25 to 1.0 g per day | Brief exposure to physical stress | 598 marathon runners, skiers and soldiers, placebo comparator | 6 |
| Cardiovascular events | 500 mg daily, oral, with a factorial vitamin E arm | Mean 8 years | 14,641 male physicians, placebo comparator | 7 |
| Kidney stones, observational intake | Supplemental intake categories up to 1,000 mg/d or more, self-reported | Median follow-up 11.3 to 11.7 years | 156,735 women and 40,536 men, no-use reference | 8 |
| Liposomal crossover | Single 500 mg oral dose, standard and liposomal | 24 h sampling, 3-day washout | 27 healthy adults, placebo and standard vitamin C comparators | 1 |
| Liposomal scoping review | 0.15 to 10 g across 10 studies | 4 to 24 h sampling | 10 studies, liposomal against non-liposomal | 5 |
Side effects reported
Sources in this part
In seven large common cold trials, 5.8% of 2490 vitamin C recipients taking 1 g per day or more reported symptoms they attributed to the medication, against 6.0% of 2066 on placebo, and "No serious symptoms were reported".6 In the Physicians' Health Study II, 500 mg daily showed no significant difference in adverse effects, including hematuria, easy bruising and epistaxis, against placebo.7 In men in the Health Professionals Follow-up Study, supplemental intake of 1,000 mg/d or more was associated with incident kidney stones (HR 1.19; 95% CI 1.01-1.40), an association the authors did not see in two cohorts of women.8 In the 1996 hospital study, oxalate and urate excretion were elevated at 1000 mg daily compared with lower doses.2
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for vitamin C. The studies read measured plasma and leukocyte vitamin C concentrations, which Purpura and colleagues describe as "efficacy markers for its bioavailability".1 Carr's review cautions that baseline status affects plasma curves, because ascorbate peaks "will only be observed in plasma following oral administration if participants already have adequate ascorbate status".5
Regulatory and anti-doping status
Sources in this part
Vitamin C (ascorbic acid) does not appear in the text retrieved of the WADA 2026 Prohibited List, which was searched for "ascorbic" and "vitamin".9 No regulator assessment or oral product label for vitamin C was retrieved among the sources, so no approval status is stated here.
What is not known
Sources in this part
The sources read give no measured plasma elimination half-life in hours for oral vitamin C, so the app's 8 hours sits beside only the 10 to 20 days quoted above. Sesso and colleagues state that "more comprehensive clinical trial data on individual vitamin C supplemental use at different doses and in other populations remain lacking".7 Hemilä and Chalker state that "Further therapeutic RCTs are warranted", noting that the shorter colds seen in regular supplementation trials were not replicated in the few therapeutic trials carried out.6 Carr's review states that none of the liposomal studies assessed ascorbate elimination, so it is uncertain whether urinary ratios match the plasma ratios.5
Frequently asked questions
What is the half-life of vitamin C?
How long does vitamin C take to peak in the blood?
What is the bioavailability of oral vitamin C?
At what daily intake does plasma vitamin C saturate?
Is vitamin C banned by WADA?
Vitamin C does not appear in the text retrieved of the WADA 2026 Prohibited List, which was searched for "ascorbic" and "vitamin".9
Does vitamin C reduce the number of colds?
In the 2013 Cochrane review, general community trials of 10,708 participants gave a pooled risk ratio of 0.97 (95% CI 0.94 to 1.00) for catching a cold.6 The same review reported colds shortened by 8% in adults and 14% in children in regular-supplementation trials, and no consistent effect in therapeutic trials.6 Five trials in 598 marathon runners, skiers and soldiers on subarctic exercises gave a pooled risk ratio of 0.48 (95% CI 0.35 to 0.64).6
Did vitamin C change cardiovascular events in the Physicians' Health Study II?
Vitamin C at 500 mg daily had no significant effect on major cardiovascular events in 14,641 male physicians (HR 0.99; 95% CI 0.89-1.11; P = .91).7
Is vitamin C supplement intake linked to kidney stones?
Does liposomal vitamin C raise blood levels more than standard vitamin C?
In a 27-person crossover of 500 mg doses, liposomal vitamin C gave a 27% higher plasma Cmax and a 21% higher plasma AUC0-24 than standard vitamin C, and the trial was funded by the product's maker.1 Across 10 studies in a 2025 scoping review, Cmax was 1.2 to 5.4-fold higher and AUC 1.3 to 7.2-fold higher in nine of them, against the app's note of about 2 to 5 times.5 The review notes that all of the studies had industry funding and/or authors employed by companies.5
Guides, tools and comparisons
References
- Purpura M, et al. Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial. Eur J Nutr 2024. PMID 39237620
- Levine M, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 1996. PMID 8623000
- Levine M, et al. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 2001. PMID 11504949
- Padayatty SJ, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004. PMID 15068981
- Carr AC. Do Liposomal Vitamin C Formulations Have Improved Bioavailability? A Scoping Review Identifying Future Research Directions. Basic Clin Pharmacol Toxicol 2025. PMID 40506693
- Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013. PMID 23440782
- Sesso HD, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008. PMID 18997197
- Ferraro PM, et al. Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones. Am J Kidney Dis 2016. PMID 26463139
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list